Human telomerase is a unique reverse transcriptase that is expressed in multiple cancers, but not in the vast majority of normal cells. The enzyme is responsible for telomere protection and maintenance, and supports the proliferative immortality of cancer cells. Thus, it has been proposed that the speci®c inhibition of telomerase activity in tumors might have signi®cant and bene®cial therapeutic eects. To this goal we have designed, synthesized, and evaluated several oligonucleotide N3'?P5' phosphoramidates as telomerase inhibitors. These oligonucleotides are complementary to the template region of the RNA domain of telomerase (hTR). The prepared compounds were evaluated in HME50-5E breast epithelial cells, where their eects on telomerase activity were determined using a cell-based telomerase (TRAP) assay at 24 as well as 72 h after exposure to compounds. The oligo-N3'?P5' phosphoramidate inhibited telomerase activity in cells in the presence of the cellular up-take enhancer (FuGENE6 TM ) in a dose-and sequence-dependent manner, with IC 50 values of approximately 1 nM. Inhibition of telomerase activity by this compound without the lipid carrier was not ecient. However, the isosequential oligonucleotide N3'?P5' thio-phosphoramidate was able to inhibit telomerase activity with or without lipid carriers at nM, or low-mM concentrations, respectively. This inhibition of telomerase activity in HME50-5E cells by the oligonucleotide thio-phosphoramidates was also sequence speci®c. Long-term treatment of the cells with 0.5 mM of FuGENE6 formulated 13-mer thio-phosphoramidates, fully complementary to hTR, resulted in gradual telomere shortening, followed by cellular senescence and apoptosis, as would be predicted for a telomerase inhibitor. The mismatched control compound had no eect on cell proliferation. The results suggest that the oligonucleotide N3'?P5' phosphoramidates, and particularly thio-phosphoramidates, might be further developed as selective anti-telomerase reagents.
Human telomerase is a unique reverse transcriptase that is expressed in multiple cancers, but not in the vast majority of normal cells. The enzyme is responsible for telomere protection and maintenance, and supports the proliferative immortality of cancer cells. Thus, it has been proposed that the speci®c inhibition of telomerase activity in tumors might have signi®cant and bene®cial therapeutic eects. To this goal we have designed, synthesized, and evaluated several oligonucleotide N3'?P5' phosphoramidates as telomerase inhibitors. These oligonucleotides are complementary to the template region of the RNA domain of telomerase (hTR). The prepared compounds were evaluated in HME50-5E breast epithelial cells, where their eects on telomerase activity were determined using a cell-based telomerase (TRAP) assay at 24 as well as 72 h after exposure to compounds. The oligo-N3'?P5' phosphoramidate inhibited telomerase activity in cells in the presence of the cellular up-take enhancer (FuGENE6   TM   ) in a dose-and sequence-dependent manner, with IC 50 values of approximately 1 nM. Inhibition of telomerase activity by this compound without the lipid carrier was not ecient. However, the isosequential oligonucleotide N3'?P5' thio-phosphoramidate was able to inhibit telomerase activity with or without lipid carriers at nM, or low-mM concentrations, respectively. This inhibition of telomerase activity in HME50-5E cells by the oligonucleotide thio-phosphoramidates was also sequence speci®c. Long-term treatment of the cells with 0.5 mM of FuGENE6 formulated 13-mer thio-phosphoramidates, fully complementary to hTR, resulted in gradual telomere shortening, followed by cellular senescence and apoptosis, as would be predicted for a telomerase inhibitor. The mismatched control compound had no eect on cell proliferation. The results suggest that theIntroduction Human telomerase is a complex ribonucleoprotein reverse transcriptase composed of an RNA component (hTR) and protein subunit (hTERT). The enzyme is believed responsible for the synthesis of hexanucleotide d-(TTAGGG) n telomeric repeats at chromosomal ends in dividing cells, employing termini (telomeres) of DNA as primers and a segment of its own RNA as template. Telomerase activity is detected in the vast majority of immortal cell lines, as well as in various primary human tumors. At the same time telomerase activity is not detected in most mature somatic cells (Kim et al., 1994) . Cells of constantly renewable tissues and germ line cells are the exceptions, where active telomerase is present during periods of high proliferation. The observed dierences in telomerase activity in normal versus tumor derived cells led to the hypothesis that telomerase may represent a suitable target for highly speci®c anti-cancer therapies. In brief, a treatment with a speci®c telomerase inhibitor should eventually result in telomere erosion of cancerous cells, and consequently, in their senescence and death. Following this appealing scienti®c rationale, several classes of telomerase inhibitors were prepared and evaluated. Among the compounds tested were small molecules (Naasani et al., 1998 (Naasani et al., , 1999 Bare et al., 1998; Hisatake et al., 1999) , compounds capable of interacting with DNA G-quadruplex structures (Neidle et al., 2000; Hurley et al., 2000) , dominant negative hTERTderived proteins (Hahn et al., 1999) , antisense RNA (Feng et al., 1995; Yamaguchi et al., 1999) , and various types of oligonucleotides, including DNA phosphodiesters (Glukhov et al., 1998) , 2-5A tethered phosphodiesters (Kondo et al., 1998) , phosphorothioates (Norton et al., 1996; Matthes and Lehmann, 1999; Sharma et al., 1996) , phosphoramidates (Gryaznov et al., 2001) , 2'-O-Methyl and 2'-O-(Methoxy-ethyl) phosphorothioate chimera (Pitts and Corey, 1998; Elayadi et al., 2001) , ribozymes (Wan et al., 1998) , and PNA molecules (Norton et al., 1996) . The eects of DNA, PNA and 2'-modi®ed RNA oligonucleotides reportedly were sequence speci®c, unlike the activity of the majority of earlier generation of phosphorothioates oligomers (Matthes and Lehman, 1999) .
In the recently reported crucial proof-of-principle studies, the treatment of various tumor-derived cell lines with oligonucleotides or protein based telomerase inhibitors resulted in cellular senescence (Herbert et al., 1999; Hahn et al., 1999) . The onset of cellular senescence was observed to be in direct correlation with the length of telomeres; cells with relatively short telomeres required much shorter treatments than the ones with longer telomeres (Hahn et al., 1999) .
In this study we present our data describing evaluation of oligonucleotide N3'?P5' phosphoramidates and thio-phosphoramidates as telomerase inhibitors in vivo in HME50-5E cells (spontaneously immortalized human breast epithelial cell line). The obtained results indicate that these compounds are ecient and sequence-speci®c telomerase inhibitors with good potential for further development as promising anti-cancer agents.
Results and Discussion
The RNA component of telomerase hTR represents an attractive target for oligonucleotide-based inhibitors. Among other functionally and structurally important regions (Chen et al., 2000) , it contains a crucial eleven nucleotides long`template region', part of which serves as the template for telomere elongation by TTAGGG repeats. Another part of this region may also be involved in chromosomal end recognition by telomerase.
We designed and prepared several 13-mer 2'-deoxyoligonucleotide N3'?P5' phosphoramidates and thio-phosphoramidates (Figure 1 ), complementary to the template region of hTR. These compounds form very stable, yet sequence-speci®c duplexes with complementary RNA strands, while remaining highly resistant to hydrolysis by cellular nucleases (Gryaznov, 1999; Pongracz and Gryaznov, 1999) . Thus, the melting temperature (T m ) for the complexes formed by the N3'?P5' phosphoramidate oligonucleotides np-TAGGGTTAGACAA (1) and np-CAGTTAGGGT-TAG (2) with RNA was 72.48C and 73.08C respectively, under close to physiological conditions (in PBS Figure 1 General structure of oligonucleotide N3'?P5' phosphoramidates ± (a), and N3'?P5'-thio-phosphoramidates ± (b) Figure 2 Dose-dependent inhibition activity by thio-phosphoramidate oligomer 5 delivered into HME50-5E cells by using FuGENE6 lipid, as measured 24 h post transfection. After transfection, cells were collected and telomerase activity was measured for 500 cell equivalents per lane using a radiolabeled oligonucleotide primer and a polymerase chain reaction (PCR)-based TRAP assay. Labeled PCR reaction products were resolved on polyacrylamide gels and visualized by PhosphorImaging. A ladder of bands represents the extension of the substrate primer by telomerase. Five hundred cell equivalents from H1299 cells served as positive control for the assay. Lysis buer alone served as a negative control Figure 3 Dose-dependent inhibition activity by thio-phosphoramidate oligomer 4 delivered into HME50-5E cells with or without the use of FuGENE6 lipid, as measured 24 h post transfection. After transfection, cells were collected and telomerase activity was measured for 500 cell equivalents per lane using a radiolabeled oligonucleotide primer and a polymerase chain reaction (PCR)-based TEAP assay. Labeled PCR reaction products were resolved on polyacrylamide gels and visualized by PhosphorImaging. A ladder of bands represents the extension of the substrate primer by telomerase. Five hundred cell equivalents from H1299 cells served as positive control for the assay. Lysis buer alone served as a negative control buer). The high thermodynamic stability of complexes formed by these oligonucleotides with RNA, we believe, is crucial for their ability to recognize and bind, via duplex formation to hTR, and consequently to inhibit the enzyme. Another important factor is the position of the targeted site on hTR. It is also important to note that the mismatch control oligonucleotide np-TAGGTGTAAGCAA (mismatched nucleosides are in bold and underlined) (3), having the same nucleoside composition, formed much less stable duplexes with the same RNA strand with T m value of *218C.
The isosequential N3'?P5' thio-phosphoramidate oligonucleotides (NPS) formed duplexes with RNA and demonstrated similar thermal stability ± T m values for nps-TAGGGTTAGACAA, nps-CAGTTAGGGT-TAG, and nps-TAGGTGTAAGCAA were 70.08C, 70.58C, and 5208C, respectively. These compounds were designated as 4, 5, and 6, respectively.
Following the duplex stability studies, the ability of oligonucleotide N3'?P5' phosphoramidates to inhibit telomerase activity was evaluated in HME50-5E cells. The cells were exposed to varying concentrations of the compounds in the absence or presence of cationic lipids FuGENE6 TM . Telomerase activity was determined as a function of the oligonucleotide treatment using a cellbased TRAP assay (Kim et al., 1994) 24 h after exposure to the compounds. The obtained data indicate that hTR complementary oligonucleotide phosphoramidates (NP's) very eciently inhibited telomerase activity in cells in the presence of the cellular uptake enhancer, with IC 50 value of *0.5 ± 1 mM, whereas a mismatched control compound had no eect. In the absence of lipid carrier the antitelomerase activity of the NP compound was noticeably lower, with IC 50 value of approximately 20 mM, with mismatched control oligonucleotide not being active at concentrations up to 100 mM (data not shown). Inecient cellular up-take or intracellular distribution, (such as endosomal sequestration) of lipid un-formulated NP oligonucleotides is likely a key factor reducing the activity of these compounds in cells in the absence of lipid carriers.
We next analysed the eects of telomerase-addressed thio-phosphoramidate (NPS) oligonucleotides in HME50-5E cells. The experiments were conducted Figure 4 Inhibition of telomerase activity during the long-term treatment by thio-phosphoramidates 4 and 5 delivered into HME50-5E cells with or without the use of FuGENE6 lipid, as measured 3 days post transfection. After transfection, cells were collected and telomerase activity was measured for 500 cell equivalents per lane using a radiolabeled oligonucleotide primer and a polymerase chain reaction (PCR)-based TRAP assay. Labeled PCR reaction products were resolved on polyacrylamide gels and visualized by PhosphorImaging. A ladder of bands represents the extension of the substrate primer by telomerase Figure 5 Eects of match 4, 5, or mismatch 6 thio-phosphoramidate oligonucleotides (formulated with FuGENE6) on HME50-5E cell growth during long-term treatment experiments. The concentration of all oligonucleotide was 500 nM Figure 6 Measurement of telomere restriction fragment length (TRF) in HME50-5E cells treated (long-term, see Figure 5 ) with match thio-phosphoramidate oligomers 4, 5, or mismatch 6. Equivalent amounts of chromosomal DNA were loaded in each lane. The TRF lengths are expressed as kilobase pairs
Phosphoramidates as telomerase inhibitors B Shea-Herbert et al similarly to the ones with their NP counterparts. The obtained data demonstrate that NPS oligonucleotides were signi®cantly more ecient telomerase inhibitors, both with and without cellular up-take enhancers, than the parent phosphoramidate compounds. Thus, the IC 50 values for telomerase inhibition by oligonucleotides 4 and 5 were *5 nM and * 0.5 nM respectively, both in presence of FuGENE6 TM . At the same time mismatched control NPS compound 6 was not active, with an IC 50 value much higher than 1000 nM. Importantly, even in absence of lipid carrier NPS oligonucleotides were able to inhibit telomerase in cells; IC 50 value for compound 4 was approximately 0.5 mM, whereas for the control oligonucleotide 6 it was more than 20 mM. Characteristic gel pro®les for cell-based TRAP analysis of telomerase inhibition by NPS oligonucleotides are presented in Figures 2 and 3 .
Furthermore, the eects of telomerase-speci®c NPS oligonucleotides on cellular proliferation were tested in long-term assays. HME50-5E cells were treated with NPS compounds 4, 5 and 6 in the presence or absence of FuGENE6 TM at concentrations of 0.5 mM or 25 mM, respectively. The oligonucleotides were added to the cells on every fourth-to-®fth day. Telomerase activity, as well as cellular proliferation (population doublings) was measured during the course of the experiment. The telomerase activity in cells transfected with FuGEN-E6 TM formulated 4 and 5 oligonucleotides was reduced to practically undetectable levels, as determined 3 days post addition of the compounds. Mismatched control 6 again did not aect the enzyme at this concentration (Figure 4) . In contrast, un-formulated oligonucleotides exerted a much weaker anti-telomerase eect, even at 50-fold higher doses (Figure 4) . Inhibition of telomerase activity by NPS oligonucleotides 4 and 5 resulted in reduction of the cellular proliferation rate, culminating in the onset of cellular senescence at approximately day 100, followed by massive apoptosis at day 115 of the experiment. At the same time the cells, which were transfected with the mismatched control compound 6, proliferated at the same rate as the untreated counterparts ( Figure 5) . Moreover, inhibition of telomerase activity by NPS oligonucleotides was accompanied by concomitant reduction in the average telomere length, from *3 kb to *1.9 kb, at the time of senescence, as determined by TRF analysis (Figure 6 ). The length of the shortest telomeric fragments was reduced from *1.9 kb to *0.9 kb. The un-formulated (without FuGENE6 TM ) NPS oligonucleotides did not signi®cantly change either cellular proliferation or the length of telomeres in comparison with untreated cells (data not shown). The dramatic dierence in the observed eects of the NPS oligonucleotides with versus without lipids is likely due to the signi®cantly lower intracellular or intranuclear concentration of oligonucleotides available for interaction with telomerase in the absence of lipid carrier such as FuGENE6 TM , resulting in a relatively low level of telomerase inhibition in the cells used. Consequently, we would like to suggest that very high, almost complete level of telomerase inhibition, as was achieved only with lipid formulated NPS oligonucleotides 4 and 5 (see Figure 4) , is crucial for induction of telomere shortening and the onset of cellular senescence. In HME50-5E cells, lower levels of telomerase inhibition by un-formulated NPS compounds apparently are not sucient to cause telomere length reduction.
In summary, oligonucleotide N3'?P5' phosphoramidates and thio-phosphoramidates were designed, prepared, and studied as telomerase inhibitors in cells. The telomerase inhibiting activity of these compounds is highly sequence-speci®c and dependent on their ability to form stable duplexes with the template region of hTR. The oligonucleotide thio-phosphoramidates were signi®cantly more potent telomerase inhibitors than the cognate phosphoramidate compounds, both with or without a cellular up-take enhancer. The NPS oligonucleotides inhibit telomerase activity in immortal HME50-5E cells with IC 50 values of 0.5 ± 5 nM and 0.5-1 mM with and without lipid carrier FuGENE6 TM , respectively. Mismatched control oligonucleotides were completely ineective at the concentrations used. Inhibition of telomerase activity in these cells eventually resulted in a gradual reduction in the length of telomeres, followed by the onset of cellular senescence and apoptosis.
The results obtained warrant further and thorough evaluation of these compounds in in vivo and in vivo systems as ecient and speci®c anti-telomerase agents with good therapeutic anti-cancer potential.
